Company research
STANDARD BIOTOOLS INC.
CIK 1162194Updated Sep 24, 2026
SecurityLAB · NASDAQ · equity
Historical securities (1)
FLDM · OTC · equity · closed Apr 5, 2022Name history
FLUIDIGM CORP · through Apr 1, 2022
LAB price & chart
Loading TradingView…
NASDAQ:LAB on TradingView ↗About the company
Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. For Research Use Only. Not for use in diagnostic procedures.
In the news
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 ↗
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy News provided by Illumina, Inc. Jun 23, 2025, 07:13 ET Share this article Share to X Share this article Share to X Combines highly complementary proteomics expertise with Illumina's in ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 567,754,000Source | 612,344,000Source | 323,067,000Source | 390,310,000Source |
| Property, Plant and Equipment, NetUSD | 19,275,000Source | 42,556,000Source | 24,187,000Source | 25,652,000Source |
| GoodwillUSD | — | 111,297,000Source | 106,317,000Source | 106,251,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 28,954,000Source | 1,400,000Source | 12,600,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 120,863,000Source | 166,728,000Source | 51,704,000Source | 81,309,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 13,431,000Source | 33,608,000Source | 19,660,000Source | 17,280,000Source |
| Inventory, NetUSD | 19,981,000Source | 40,737,000Source | 20,533,000Source | 21,473,000Source |
| Assets, CurrentUSD | 454,264,000Source | 375,880,000Source | 158,215,000Source | 208,815,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,871,000Source | 8,661,000Source | 3,127,000Source | 4,278,000Source |
| Operating Lease, Right-of-Use AssetUSD | 26,732,000Source | 28,828,000Source | 30,663,000Source | 33,883,000Source |
| Other Assets, NoncurrentUSD | 3,154,000Source | 6,301,000Source | 2,285,000Source | 3,109,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 143,463,000Source | 140,622,000Source | 159,865,000Source | 160,524,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 404,000Source | 396,000Source | 83,000Source | 80,000Source |
| Additional Paid in CapitalUSD | 1,732,393,000Source | 1,702,219,000Source | 860,816,000Source | 847,008,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,260,547,000Source | -1,185,651,000Source | -1,000,752,000Source | -926,096,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,492,000Source | 1,225,000Source | -2,221,000Source | -1,896,000Source |
| Stockholders' Equity Attributable to ParentUSD | 424,291,000Source | 471,722,000Source | -148,051,000Source | -81,467,000Source |
| Liabilities and EquityUSD | 567,754,000Source | 612,344,000Source | 323,067,000Source | 390,310,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 108,308,000Source | 65,894,000Source | 109,327,000Source | 43,443,000Source |
| Operating Lease, Liability, CurrentUSD | 5,490,000Source | 6,228,000Source | 4,323,000Source | 3,682,000Source |
| Accounts Payable, CurrentUSD | 5,407,000Source | 12,282,000Source | 9,236,000Source | 7,914,000Source |
| Operating Lease, Liability, NoncurrentUSD | 25,038,000Source | 26,469,000Source | 30,374,000Source | 34,081,000Source |
| Deferred Income Tax Liabilities, NetUSD | 810,000Source | 1,081,000Source | 841,000Source | 1,055,000Source |
| Other Liabilities, NoncurrentUSD | 1,215,000Source | 6,962,000Source | 1,065,000Source | 961,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 29,783,000Source | 30,739,000Source | 9,152,000Source | 6,175,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 166,799,000Source |
| Deferred Tax Liabilities, NetUSD | — | 943,000Source | 706,000Source | 824,000Source |
| Long-term DebtUSD | — | 299,000Source | 63,513,000Source | — |
| Short-term InvestmentsUSD | — | — | — | 84,475,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 12,673,000Source | 6,223,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 29,613,000Source | 31,732,000Source | 13,123,000Source | 14,880,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,361,000Source | -8,967,000Source | 2,991,000Source | -1,063,000Source |
| Increase (Decrease) in InventoriesUSD | 11,524,000Source | 9,879,000Source | 4,914,000Source | 8,470,000Source |
| Increase (Decrease) in Accounts PayableUSD | 2,437,000Source | -12,975,000Source | 1,618,000Source | -2,776,000Source |
| Deferred Income Tax Expense (Benefit)USD | -38,768,000Source | 237,000Source | -118,000Source | -3,322,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -74,343,000Source | -143,454,000Source | -43,287,000Source | -89,370,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 1,385,000Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 27,409,000Source | 363,174,000Source | 20,237,000Source | -88,127,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 8,303,000Source | 8,355,000Source | 2,831,000Source | 3,825,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 484,000Source | 459,000Source | 139,000Source | 211,000Source |
| Payments for Repurchase of Common StockUSD | 0Source | 40,490,000Source | 5,414,000Source | 563,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 570,000Source | -102,616,000Source | -6,809,000Source | 230,758,000Source |
| Repayments of Long-term DebtUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -45,522,000Source | 116,319,000Source | -29,825,000Source | 52,857,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 123,296,000Source | 168,818,000Source | 52,499,000Source | 82,324,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 15,000Source | 3,088,000Source | 3,819,000Source | 3,493,000Source |
| Income Taxes Paid, NetUSD | -73,000Source | 607,000Source | 801,000Source | 309,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 842,000Source | -785,000Source | 34,000Source | -404,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 25,774,000Source | 31,732,000Source | 13,123,000Source | 14,880,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 770,000Source | 830,000Source |
| Amortization of Intangible AssetsUSD | 1,715,000Source | 4,346,000Source | 11,200,000Source | 11,528,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 166,799,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | — |
| DepreciationUSD | 6,900,000Source | — | 3,400,000Source | 2,800,000Source |
| Depreciation, Amortization and Accretion, NetUSD | 9,262,000Source | 12,515,000Source | 3,980,000Source | 3,499,000Source |
| GoodwillUSD | — | 111,297,000Source | 106,317,000Source | 106,251,000Source |
| Goodwill, Impairment LossUSD | 0Source | — | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | 0Source | 0Source | 3,526,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -58,826,000Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | -16,070,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | -37,876,000Source | 573,000Source | 452,000Source | -2,830,000Source |
| LitigationSettlementLossUSD | — | 600,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -74,896,000Source | -138,885,000Source | -74,656,000Source | -190,098,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -74,896,000Source | -184,899,000Source | — | — |
| Operating ExpensesUSD | 152,792,000Source | 259,498,000Source | 127,050,000Source | 214,153,000Source |
| Other Nonoperating Income (Expense)USD | 4,394,000Source | -5,172,000Source | 6,963,000Source | 1,255,000Source |
| Proceeds from Stock Options ExercisedUSD | 531,000Source | 1,152,000Source | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | -602,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 85,331,000Source | 174,432,000Source | 106,340,000Source | 97,948,000Source |
| Cost of RevenueUSD | 42,788,000Source | 90,170,000Source | 55,890,000Source | — |
| Selling, General and Administrative ExpenseUSD | 109,861,000Source | 156,608,000Source | 87,541,000Source | 114,758,000Source |
| Operating Income (Loss)USD | -110,249,000Source | -175,236,000Source | -76,600,000Source | -116,205,000Source |
| Other Nonoperating Income (Expense)USD | 4,394,000Source | -5,172,000Source | 6,963,000Source | 1,255,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -96,702,000Source | -138,312,000Source | -74,204,000Source | -192,928,000Source |
| Income Tax Expense (Benefit)USD | -37,876,000Source | 573,000Source | 452,000Source | -2,830,000Source |
| Net Income (Loss) Attributable to ParentUSD | -74,896,000Source | -138,885,000Source | -74,656,000Source | -190,098,000Source |
| Earnings Per Share, BasicUSD per share | -0.2Source | -0.52Source | -0.94Source | -2.43Source |
| Earnings Per Share, DilutedUSD per share | -0.2Source | -0.52Source | -0.94Source | -2.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 381,623,000Source | 353,245,000Source | 79,160,000Source | 78,305,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 381,623,000Source | 353,245,000Source | 79,160,000Source | 78,305,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,715,000Source | 4,346,000Source | 11,200,000Source | 11,528,000Source |
| Business Combination, Acquisition Related CostsUSD | 2,162,000Source | 27,979,000Source | 6,485,000Source | — |
| Current Income Tax Expense (Benefit)USD | 892,000Source | 336,000Source | 570,000Source | 492,000Source |
| Debt Securities, Gain (Loss)USD | — | 0Source | 0Source | -13,719,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 12,300,000Source | — | — |
| Goodwill, Impairment LossUSD | 0Source | — | 0Source | 0Source |
| Gross ProfitUSD | 42,543,000Source | 84,262,000Source | 50,450,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -58,826,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -68,532,000Source | -110,938,000Source | -40,587,000Source | -174,041,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.15Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.15Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | -16,070,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 4,567,000Source | 4,331,000Source |
| InterestExpenseOperatingUSD | 26,000Source | 3,316,000Source | — | — |
| Interest Income, OperatingUSD | 9,179,000Source | 20,199,000Source | — | — |
| LitigationSettlementLossUSD | — | 600,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -74,896,000Source | -184,899,000Source | — | — |
| Operating ExpensesUSD | 152,792,000Source | 259,498,000Source | 127,050,000Source | 214,153,000Source |
| Research and Development ExpenseUSD | 25,987,000Source | 62,411,000Source | 25,948,000Source | 38,498,000Source |
Offerings
Registration 333-297560
Filing attachments
lab-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 lab-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Standard BioTools Reports Second Quarter 2026 Financial Results BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent Highlights: • Second quarter 2026 revenue of $20.1 million • 1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-year • Merger with Treel…
Read attachment ↗ef20078901_ex99-1.htm · 8-K · 2026-07-28
EX-99.1 3 ef20078901_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms Receives Approximately $30 Million in Negotiated Buyout Related to Contin…
Read attachment ↗ny20077604x1_ex107.htm · S-4 · 2026-07-20
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) STANDARD BIOTOOLS INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regi…
Read attachment ↗ny20077604x1_ex99-1.htm · S-4 · 2026-07-20
EX-99.1 7 ny20077604x1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Centerview Partners LLC 31 West 52nd Street New York, NY 10019 July 20, 2026 Centerview Partners LLC 31 West 52nd Street New York, NY 10019 July 20, 2026 ─────────────────────────── The Board of Directors Standard BioTools Inc. 50 Milk Street, 10th Floor Boston, MA 02109 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated June 6, 2026, to the Board of Directors of Sta…
Read attachment ↗ny20077604x1_ex99-2.htm · S-4 · 2026-07-20
EX-99.2 8 ny20077604x1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 CONSENT OF UBS SECURITIES LLC We hereby consent to the use of our opinion letter dated June 5, 2026 to the Special Committee of the Board of Directors of Standard BioTools Inc. (the “Special Committee”) included as Annex C to the Proxy Statement/Prospectus which forms a part of the Registration Statement on Form S-4 of Standard BioTools Inc. relating to the proposed merger of TreeLine Biosciences, Inc. with Standard BioTools Inc.,…
Read attachment ↗tm2617100d1_ex99-1.htm · 8-K · 2026-06-08
EX-99.1 6 tm2617100d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Standard BioTools and Treeline Biosciences Announce Merger Agreement Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co-founder Josh Bilenker, MD, and experienced team of proven drug developers Treeline’s pipeline includes three Phase 1 programs with multiple anticipate…
Read attachment ↗